•
Jun 30, 2023

AN2 Therapeutics Q2 2023 Earnings Report

EPS
-$0.81
Previous year: -$0.53
+52.8%
R&D Expenses
$13.5M
G&A Expenses
$3.06M
Other Income, Net
$797K
Cash and Equivalents
$40.8M
Previous year: $40.6M
+0.5%
Total Assets
$98.9M
Previous year: $120M
-17.6%

AN2 Therapeutics

AN2 Therapeutics